DOCSLIB.ORG

Glucuronidation of the Broadspectrum Antiviral Drug Arbidol by UGT Isoforms

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Glucuronidation of the Broadspectrum Antiviral Drug Arbidol by UGT Isoforms bs_bs_banner Research Paper Journal of Pharmacy And Pharmacology Glucuronidation of the broad-spectrum antiviral drug arbidol by UGT isoforms Jin-Hui Songa,*, Zhong-Ze Fangb,e,*, Liang-Liang Zhud, Yun-Feng Caoc, Cui-Min Hue, Guang-Bo Ged and De-Wei Zhaoa aOrthopedics Department, Affiliated Zhongshan Hospital of Dalian University, Dalian, bLiaoning Medical University, Jinzhou, cKey Laboratory of Contraceptives and Devices Research (NPFPC), Shanghai Engineer and Technology Research Center of Reproductive Health Drug and Devices, Shanghai Institute of Planned Parenthood Research, Shanghai, dLaboratory of Pharmaceutical Resource Discovery, Dalian Institute of Chemical Physics, Chinese Academy of Sciences, Dalian, China and eLaboratory of Metabolism, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA Keywords Abstract arbidol; glucuronidation; UDP-glucuronosyltransferases (UGTs) Objectives The aim of this work was to identify the uridine glucuronosyltrans- ferase (UGT) isoforms involved in the metabolism of the broad-spectrum antivi- Correspondence ral drug arbidol. De-Wei Zhao, Orthopedics Department, Methods A human liver microsome (HLM) incubation system was employed to Affiliated Zhongshan Hospital of Dalian catalyse the formation of arbidol glucuronide. The glucuronidation activity of University, Dalian 116 001, China. E-mail: [email protected] commercially recombinant UGT isoforms towards arbidol was screened. A combi- nation of kinetic analysis and chemical inhibition study was used to determine the Received June 21, 2012 UGT isoforms involved in arbidol’s glucuronidation. Accepted November 14, 2012 Key findings The arbidol glucuronide was detected when arbidol was incubated with HLMs in the presence of UDP-glucuronic acid. The Eadie–Hofstee plot doi: 10.1111/jphp.12014 showed that glucuronidation of arbidol was best fit to the Michaelis–Menten Ϯ *These two authors equally contributed to kinetic model, and Km and apparent Vmax were calculated to be 8.0 0.7 mm and Ϯ this work. 2.03 0.05 nmol/min/mg protein, respectively. Assessment of a panel of recom- binant UGT isoforms revealed that UGT1A1, UGT1A3 and UGT1A9 could cata- lyse the glucuronidation of arbidol. Kinetic analysis and chemical inhibition study demonstrated that UGT1A9 was the predominant UGT isoform involved in arbidol glucuronidation in HLMs. Conclusions The major contribution of UGT1A9 towards arbidol glucuronida- tion was demonstrated in this study. Introduction Arbidol, ethyl-6-bromo-4-[(dimethylamino)-methyl]-5- dose of arbidol, the time to reach maximal plasma concen- hydroxy-1-methyl-2-[(phenylthio) methyl]-indole-3- trations (Tmax) was determined to be 1.2 h. The half-life 1 carboxylate (Figure 1), is an antiviral drug developed by the (t /2) of the drug in the body is 17–21 h and about 40% of Chemical Drug Center of All Russian Research Institute of drug is excreted unchanged.[7] It is metabolized in the liver Pharmaceutical Chemistry together with the Institute of and arbidol glucuronide is a major metabolite in human Medical Radiology.[1] It has been demonstrated to exhibit urine.[8] inhibitory activity towards various types of viruses, such as The human uridine glucuronosyltransferases (UGTs) are influenza virus, respiratory syncytial virus, adenovirus, rhi- membrane proteins of the endoplasmic reticulum and can novirus, parainfluenza virus, hepatitis B virus, hepatitis C conjugate various endogenous substances and exogenous virus and coxsackie virus.[2–6] Therefore, arbidol is regarded compounds.[9] Glucuronidation reactions catalysed by as a broad-spectrum antiviral compound. Recently, arbidol UGTs account for >35% of all phase II drug metabolism.[10] has been approved for the treatment of influenza in Russia, UGT-mediated metabolism is normally regarded as a China and some European countries. detoxifying process, and glucuronides have greater polarity The pharmacokinetic behaviour of arbidol has been than the parent drugs. Nevertheless, some glucuronides reported in a previous publication.[7] After a single 50-mg have been reported to show pharmacological and © 2012 The Authors. JPP © 2012 Royal Pharmaceutical Society 2013 Journal of Pharmacy and Pharmacology, 65, pp. 521–527 521 UGT isoforms for arbidol glucuronidation Jin-Hui Song et al. CH3 donors signed informed consents approved by the local ethical committee. Information on the medication history N of the sample donors was not gained. A panel of human O CH3 H3C liver microsomes (HLMs) was prepared from 12 liver O samples obtained from male and female patients by differ- ential ultracentrifugation as described previously.[13,14] HO Microsomal protein concentrations were determined by the Lowry method with bovine serum albumin as standard.[15] A panel of recombinant human UGT supersomes (UGT1A1, UGT1A3, UGT1A4, UGT1A6, UGT1A9, N S Br UGT2B4, UGT2B7, UGT2B15 and UGT2B17) expressed in baculovirus-infected insect cells were purchased from BD CH3 Gentest Corp. (Woburn, MA, USA). Figure 1 The structure of arbidol. Arbidol glucuronidation assay [11] toxicological effects. The human UGT superfamily is A typical incubation mixture (200 ml total volume) was classified into two families (UGT1 and UGT2) and three composed of 50 mm Tris-HCl buffer (pH = 7.4), 5 mm subfamilies (UGT1A, UGT2A and UGT2B) based on their MgCl2,5mm UDPGA, 25 mg/ml alamethicin, 10 mm [12] sequence identity. The following UGT enzymes are d-saccharic acid 1,4-lactone, 100 mm arbidol and 0.5 mg/ml expressed in the human liver: UGT1A1, UGT1A3, UGT1A4, HLMs. Arbidol was dissolved in methanol and the final UGT1A6, UGT1A9, UGT2B4, UGT2B7, UGT2B10, concentration of methanol in the incubation system was UGT2B11, UGT2B15, UGT2B17 and UGT2B28. 1% (v/v). After pre-incubation at 37°C for 5 min, the reac- Identification of drug-metabolizing enzymes (DMEs) is tion was initiated by addition of UDPGA. The reaction very important to understand the variation in drug effect mixture was incubated at 37°C for 1 h and terminated by and metabolism. Moreover, identification of DMEs could addition of 100 ml ice-cold acetonitrile. The mixture was provide pivotal information for potential drug–drug inter- centrifuged at 20 000g for 10 min and a portion of the actions, and the information provided can be used to guide supernatant fraction was transferred to a 0.3-ml auto- clinical practice and reduce side effects in clinical treatment. injector vial for HPLC analysis. Control incubations Therefore, the objective of this experiment was to investi- (without UDPGA, without substrate or without micro- gate the glucuronidation of arbidol using an in-vitro somes) were performed to ensure that the formation of human liver microsomal system. Human UGT isoforms metabolites was microsome- and UDPGA-dependent. The responsible for the formation of metabolites were identified HPLC system (Shimadzu, Kyoto, Japan) contained an SCL- by screening with recombinant expressed UGT isoforms 10A system controller, two LC-10AT pumps, a SIL-10A and chemical inhibition study. To our knowledge, this is the auto-injector, an SPD-10AVP UV detector and a C18 column first study to investigate the UGT isoforms involved in the (4.6 ¥ 150 mm, 5 mm, Kromasil, Sigma-Aldrich) was used glucuronidation of arbidol. to separate arbidol and its metabolites. The mobile phase consisted of CH3CN (A) and H2O containing 0.5% (v/v) Materials and Methods formic acid (B). The following gradient condition was used: 0–15 min, 98–10% B; 15–20 min, 10% B; 20–25 min, 5% B; Materials 25–35 min, 98% B. The flow rate of the mobile phase was Arbidol hydrochloride (purity > 98%) was obtained from set at 1 ml/min. The injection volume was 30 ml and the the National Institute for the Control of Pharmaceutical scan wavelength was set at 316 nm. Due to the absence of and Biological Products (Beijing, People’s Republic of authentic standards for arbidol glucuronide, quantification China). Alamethicin, magnesium chloride (MgCl2), of the glucuronide in the incubation mixtures was per- d-saccharic acid 1,4-lactone, UDP-glucuronic acid triso- formed using a standard curve of arbidol. The calculation dium salt (UDPGA), androsterone, mefenamic acid and curve was generated by peak area of arbidol over the con- erlotinib were purchased from Sigma-Aldrich (St Louis, centration range 0.1–100 mm. The curve was linear over this MO, USA). All other reagents were of HPLC grade or of the concentration range (r2 > 0.99). The limits of detection and highest grade commercially available. quantification were determined at signal-to-noise ratios of Human liver samples were obtained from Dalian Medical 3 and 10, respectively. The accuracy and precision of the University (Dalian, Liaoning province, China) with the back-calculated values for each concentration were less approval of the local ethics committee at the university. All than 5%. © 2012 The Authors. JPP © 2012 522 Royal Pharmaceutical Society 2013 Journal of Pharmacy and Pharmacology, 65, pp. 521–527 Jin-Hui Song et al. UGT isoforms for arbidol glucuronidation Identification of arbidol glucuronide by for 20 min. For recombinant human UGT1A1, UGT1A3 mass/mass analysis and UGT1A9, 0.025 mg/ml of protein and various concen- trations of arbidol were used to determine the kinetic The arbidol glucuronide was separated and collected for parameters. Metabolite formation was linear under assay mass/mass (MS/MS) analysis. MS/MS analysis was carried conditions. The kinetic constants were estimated by nonlin- out on an ABI 4000 Q-Trap hybrid triple quadrupole linear ear regression analysis using the Michaelis–Menten equa- ion-trap mass spectrometer (Applied Biosystems, Foster tion (Equation 1): City, CA, USA). MS conditions used were as follows: ion- spray voltage, 5000; temperature, 550; collision energy, 35; vV=∗(max [ S ]) ( K m + [ S ]) (1) collision energy spread, 15. A collision-induced dissociation (CID) MS/MS spectrum was obtained to further elucidate where v is the rate of reaction, Vmax is the maximum veloc- the structure of metabolite. Data were processed using ity, Km is the Michaelis constant (substrate concentration at Analyst 4.1 software (Applied Biosystems). 0.5 Vmax) and [S] is the substrate concentration.
Load more

Recommended publications
  • CASODEX (Bicalutamide)
    HIGHLIGHTS OF PRESCRIBING INFORMATION • Gynecomastia and breast pain have been reported during treatment with These highlights do not include all the information needed to use CASODEX 150 mg when used as a single agent. (5.3) CASODEX® safely and effectively. See full prescribing information for • CASODEX is used in combination with an LHRH agonist. LHRH CASODEX. agonists have been shown to cause a reduction in glucose tolerance in CASODEX® (bicalutamide) tablet, for oral use males. Consideration should be given to monitoring blood glucose in Initial U.S. Approval: 1995 patients receiving CASODEX in combination with LHRH agonists. (5.4) -------------------------- RECENT MAJOR CHANGES -------------------------- • Monitoring Prostate Specific Antigen (PSA) is recommended. Evaluate Warnings and Precautions (5.2) 10/2017 for clinical progression if PSA increases. (5.5) --------------------------- INDICATIONS AND USAGE -------------------------- ------------------------------ ADVERSE REACTIONS ----------------------------- • CASODEX 50 mg is an androgen receptor inhibitor indicated for use in Adverse reactions that occurred in more than 10% of patients receiving combination therapy with a luteinizing hormone-releasing hormone CASODEX plus an LHRH-A were: hot flashes, pain (including general, back, (LHRH) analog for the treatment of Stage D2 metastatic carcinoma of pelvic and abdominal), asthenia, constipation, infection, nausea, peripheral the prostate. (1) edema, dyspnea, diarrhea, hematuria, nocturia, and anemia. (6.1) • CASODEX 150 mg daily is not approved for use alone or with other treatments. (1) To report SUSPECTED ADVERSE REACTIONS, contact AstraZeneca Pharmaceuticals LP at 1-800-236-9933 or FDA at 1-800-FDA-1088 or ---------------------- DOSAGE AND ADMINISTRATION ---------------------- www.fda.gov/medwatch The recommended dose for CASODEX therapy in combination with an LHRH analog is one 50 mg tablet once daily (morning or evening).
    [Show full text]
  • An Unexpected Target for Androgen Deprivation Therapy with Prognosis and Diagnostic Implications
    Author Manuscript Published OnlineFirst on October 11, 2013; DOI: 10.1158/0008-5472.CAN-13-1462 Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 1 Androgen glucuronidation: an unexpected target for androgen deprivation therapy with prognosis and diagnostic implications. Laurent Grosse1, Sophie Pâquet1, Patrick Caron1, Ladan Fazli2, Paul S. Rennie2, Alain Bélanger3 and Olivier Barbier1 1Laboratory of Molecular Pharmacology, CHU-Québec Research Centre and Faculty of Pharmacy, Laval University, Québec, Canada 2 Vancouver Prostate Centre at VGH, University of British Columbia, Vancouver, British Columbia, Canada. 3CHU-Québec Research Centre and Faculty of Medicine, Laval University, Québec, Canada Running title: Ablation therapy improves androgen glucuronidation in PCa Keywords: Prostate cancer, androgen ablation therapy, glucuronidation, biomarker, drug target. Financial support: This study was supported by grants from the Canadian Institutes of Health Research (CIHR), the Terry Fox foundation and the Canadian Foundation for Innovation. S. Pâquet is holder of scholarships from CIHR and the Fonds pour la Recherche en Santé du Québec (FRSQ). L. Grosse is supported by a scholarship from the Fonds pour l’Enseignement et la Recherche (FER) from the Faculty of Pharmacy, Laval University (Québec). O. Barbier is holder of salary grants from the CIHR (New Investigator Award #MSH95330) and FRSQ (Junior 2 Scholarship). Address correspondence to: Olivier Barbier, Ph.D. Laboratory of Molecular Pharmacology CHU-Québec Research Centre 2705, boulevard Laurier Québec (QC) G1V 4G2, Canada Phone: 418 654 2296 Fax: 418 654 2769 Email: [email protected] Conflict of interests: Authors have nothing to disclose. Downloaded from cancerres.aacrjournals.org on September 26, 2021.
    [Show full text]
  • Conjugated Estrogens Sustained Release Tablets) 0.3 Mg, 0.625 Mg, and 1.25 Mg
    PRODUCT MONOGRAPH PrPREMARIN® (conjugated estrogens sustained release tablets) 0.3 mg, 0.625 mg, and 1.25 mg ESTROGENIC HORMONES ® Wyeth Canada Date of Revision: Pfizer Canada Inc., Licensee December 1, 2014 17,300 Trans-Canada Highway Kirkland, Quebec H9J 2M5 Submission Control No: 177429 PREMARIN (conjugated estrogens sustained release tablets) Page 1 of 46 Table of Contents PART I: HEALTH PROFESSIONAL INFORMATION .........................................................3 SUMMARY PRODUCT INFORMATION ...........................................................................3 INDICATIONS AND CLINICAL USE ................................................................................3 CONTRAINDICATIONS ......................................................................................................4 WARNINGS AND PRECAUTIONS ....................................................................................4 ADVERSE REACTIONS ....................................................................................................14 DRUG INTERACTIONS ....................................................................................................20 DOSAGE AND ADMINISTRATION ................................................................................23 OVERDOSAGE ...................................................................................................................25 ACTION AND CLINICAL PHARMACOLOGY ...............................................................25 STORAGE AND STABILITY ............................................................................................28
    [Show full text]
  • Receptor Af®Nity and Potency of Non-Steroidal Antiandrogens: Translation of Preclinical ®Ndings Into Clinical Activity
    Prostate Cancer and Prostatic Diseases (1998) 1, 307±314 ß 1998 Stockton Press All rights reserved 1365±7852/98 $12.00 http://www.stockton-press.co.uk/pcan Review Receptor af®nity and potency of non-steroidal antiandrogens: translation of preclinical ®ndings into clinical activity GJCM Kolvenbag1, BJA Furr2 & GRP Blackledge3 1Medical Affairs, Zeneca Pharmaceuticals, Wilmington, DE, USA; 2Therapeutic Research Department, and 3Medical Research Department, Zeneca Pharmaceuticals, Alderley Park, Maccles®eld, Cheshire, UK The non-steroidal antiandrogens ¯utamide (Eulexin1), nilutamide (Anandron1) and bicalutamide (Casodex1) are widely used in the treatment of advanced prostate cancer, particularly in combination with castration. The naturally occurring ligand 5a-DHT has higher binding af®nity at the androgen receptor than the non-steroidal antiandrogens. Bicalutamide has an af®nity two to four times higher than 2-hydroxy¯utamide, the active metabolite of ¯utamide, and around two times higher than nilutamide for wild-type rat and human prostate androgen receptors. Animal studies have indicated that bicalutamide also exhi- bits greater potency in reducing seminal vesicle and ventral prostate weights and inhibiting prostate tumour growth than ¯utamide. Although preclinical data can give an indication of the likely clinical activity, clinical studies are required to determine effective, well-tolerated dosing regimens. As components of combined androgen blockade (CAB), controlled studies have shown survival bene®ts of ¯utamide plus a luteinising hormone-releasing hormone analogue (LHRH-A) over LHRH-A alone, and for nilutamide plus orchiectomy over orchiectomy alone. Other studies have failed to show such survival bene®ts, including those comparing ¯utamide plus orchiectomy with orchiectomy alone, and nilutamide plus LHRH-A with LHRH-A alone.
    [Show full text]
  • Pregnancy Increases Norbuprenorphine Clearance in Mice by Induction of Hepatic Glucuronidation
    1521-009X/46/2/100–108$25.00 https://doi.org/10.1124/dmd.117.076745 DRUG METABOLISM AND DISPOSITION Drug Metab Dispos 46:100–108, February 2018 Copyright ª 2018 by The American Society for Pharmacology and Experimental Therapeutics Pregnancy Increases Norbuprenorphine Clearance in Mice by Induction of Hepatic Glucuronidation Michael Z. Liao, Chunying Gao, Brian R. Phillips, Naveen K. Neradugomma, Lyrialle W. Han, Deepak Kumar Bhatt, Bhagwat Prasad, Danny D. Shen, and Qingcheng Mao Department of Pharmaceutics, School of Pharmacy, University of Washington, Seattle, Washington Received May 5, 2017; accepted November 17, 2017 ABSTRACT Norbuprenorphine (NBUP) is the major active metabolite of bupre- proteomics quantification revealed that hepatic Ugt1a1 and norphine (BUP) that is commonly used to treat opiate addiction Ugt2b1 protein levels in the same amount of total liver membrane ’ ∼ during pregnancy; it possesses 25% of BUP s analgesic activity proteins were significantly increased by 50% in pregnant mice Downloaded from and 10 times BUP’s respiratory depression effect. To optimize versus nonpregnant mice. After scaling to the whole liver with BUP’s dosing regimen during pregnancy with better efficacy and consideration of the increase in liver protein content and liver safety, it is important to understand how pregnancy affects NBUP weight, we found that the amounts of Ugt1a1, Ugt1a10, Ugt2b1, disposition. In this study, we examined the pharmacokinetics of and Ugt2b35 protein in the whole liver of pregnant mice were NBUP in pregnant and nonpregnant mice by administering the significantly increased ∼2-fold compared with nonpregnant mice. same amount of NBUP through retro-orbital injection. We demon- These data suggest that the increased systemic CL of NBUP in dmd.aspetjournals.org strated that the systemic clearance (CL) of NBUP in pregnant mice pregnant mice is likely caused by an induction of hepatic Ugt increased ∼2.5-fold compared with nonpregnant mice.
    [Show full text]
  • Drug Metabolism and Pharmacokinetics (DMPK)
    Drug Metabolism and Pharmacokinetics (DMPK) Advance Publication by J-STAGE Received; February 25, 2012 Published online; April 27, 2012 Accepted; April 19, 2012 doi; 10.2133/dmpk.DMPK-12-RG-023 Identification and Characterization of Human UDP-Glucuronosyltransferases Responsible for the In Vitro Glucuronidation of Salvianolic acid A De-en Hana,b, Yi Zhengb, Xijing Chenb, Jiake Heb, Di Zhaob, Shuoye Yangb, Chunfeng Zhanga*,Zhonglin Yanga,* aState Key laboratory of Natural Products and Functions, China Pharmaceutical University, Ministry of Education, Nanjing, P. R. China. bCenter of Drug Metabolism and Pharmacokinetics, China Pharmaceutical University, Nanjing, Jiangsu 210009, China. 1 Copyright C 2012 by the Japanese Society for the Study of Xenobiotics (JSSX) Drug Metabolism and Pharmacokinetics (DMPK) Advance Publication by J-STAGE Running title：Glucuronidation of salvianolic acid A in Vitro Corresponding Author: Chunfeng Zhang, PhD State Key laboratory of Natural Products and Functions, China Pharmaceutical University 24# Tong Jia Xiang, Nanjing 210009, PR China. E-mail: [email protected] Phone: +86 25 8337 1694 Zhonglin Yang, PhD State Key laboratory of Natural Products and Functions, China Pharmaceutical University 24# Tong Jia Xiang, Nanjing 210009, PR China. E-mail: [email protected] Phone: +86 25 8337 1694 Fax: +86 25 8337 1694 Number of text pages: 23 Number of tables: 2 Number of figures: 6 2 Drug Metabolism and Pharmacokinetics (DMPK) Advance Publication by J-STAGE ABSTRACT: Glucuronidation is an important pathway in the elimination of salvianolic acid A (Sal A), however the mechanism of UDP-glucuronosyltransferases (UGTs) in this process remains to be investigated. In this study, the kinetics s of salvianolic acid A glucuronidation by pooled human liver microsomes (HLMs), pooled human intestinal microsomes (HIMs) and 12 recombinant UGTs isozymes were investigated.
    [Show full text]
  • Section 2.6.4 Pharmacokinetics Written Summary EMTRICITABINE
    SECTION 2.6 NONCLINICAL SUMMARY Section 2.6.4 Pharmacokinetics Written Summary EMTRICITABINE/ RILPIVIRINE/ TENOFOVIR DISOPROXIL FUMARATE FIXED-DOSE COMBINATION 17 August 2010 CONFIDENTIAL AND PROPRIETARY INFORMATION Emtricitabine/Rilpivirine/Tenofovir Disoproxil Fumarate Section 2.6.4 Pharmacokinetics Written Summary Final TABLE OF CONTENTS SECTION 2.6 NONCLINICAL SUMMARY........................................................................................................1 TABLE OF CONTENTS .......................................................................................................................................2 GLOSSARY OF ABBREVIATIONS AND DEFINITION OF TERMS ..............................................................5 2.6. NONCLINICAL SUMMARY.......................................................................................................................8 2.6.4. PHARMACOKINETICS WRITTEN SUMMARY .........................................................................8 2.6.4.1. Brief Summary................................................................................................................8 2.6.4.2. Methods of Analysis .....................................................................................................14 2.6.4.2.1. Emtricitabine............................................................................................14 2.6.4.2.2. Rilpivirine ................................................................................................14 2.6.4.2.3. Tenofovir Disoproxil Fumarate
    [Show full text]
  • Product Monograph Casodex®
    PRODUCT MONOGRAPH Pr CASODEX® bicalutamide tablets 50mg Tablets Non-Steroidal Antiandrogen AstraZeneca Canada Inc. Date of Revision: 1004 Middlegate Road July 13, 2017 Mississauga, Ontario L4Y 1M4 www.astrazeneca.ca Control No. 205811 CASODEX® is a registered trademark of AstraZeneca UK Limited, used under license by AstraZeneca Canada Inc. COPYRIGHT 1995-2017 ASTRAZENECA CANADA INC. Page 1 of 32 TABLE OF CONTENTS TABLE OF CONTENTS .........................................................................................................2 PART I: HEALTH PROFESSIONAL INFORMATION .......................................................3 SUMMARY PRODUCT INFORMATION......................................................................3 INDICATIONS AND CLINICAL USE ...........................................................................3 CONTRAINDICATIONS.................................................................................................3 WARNINGS AND PRECAUTIONS ...............................................................................4 ADVERSE REACTIONS .................................................................................................8 DRUG INTERACTIONS ...............................................................................................12 DOSAGE AND ADMINISTRATION ...........................................................................13 OVERDOSAGE..............................................................................................................14 ACTION AND CLINICAL PHARMACOLOGY..........................................................14
    [Show full text]
  • Potential Assessment of UGT2B17 Inhibition by Salicylic Acid in Human Supersomes in Vitro
    molecules Article Potential Assessment of UGT2B17 Inhibition by Salicylic Acid in Human Supersomes In Vitro Hassan Salhab * , Declan P. Naughton and James Barker School of Life Sciences, Pharmacy and Chemistry, Kingston University, Kingston-Upon-Thames, London KT1 2EE, UK; [email protected] (D.P.N.); [email protected] (J.B.) * Correspondence: [email protected]; Tel.: +44-7984974741; Fax: +44-208-4179000 Abstract: Glucuronidation is a Phase 2 metabolic pathway responsible for the metabolism and excretion of testosterone to a conjugate testosterone glucuronide. Bioavailability and the rate of anabolic steroid testosterone metabolism can be affected upon UGT glucuronidation enzyme alter- ation. However, there is a lack of information about the in vitro potential assessment of UGT2B17 inhibition by salicylic acid. The purpose of this study is to investigate if UGT2B17 enzyme activity is inhibited by salicylic acid. A UGT2B17 assay was developed and validated by HPLC using a C18 reversed phase column (SUPELCO 25 cm × 4.6 mm, 5 µm) at 246 nm using a gradient elution mobile phase system: (A) phosphate buffer (0.01 M) at pH = 3.8, (B) HPLC grade acetonitrile and (C) HPLC grade methanol. The UGT2B17 metabolite (testosterone glucuronide) was quantified using human UGT2B17 supersomes by a validated HPLC method. The type of inhibition was determined by Lineweaver–Burk plots. These were constructed from the in vitro inhibition of salicylic acid at different concentration levels. The UGT2B17 assay showed good linearity (R2 > 0.99), acceptable recovery and accuracy (80–120%), good reproducibility and acceptable inter and intra-assay precision Citation: Salhab, H.; Naughton, D.P.; (<15%), low detection (6.42 and 2.76 µM) and quantitation limit values (19.46 and 8.38 µM) for Barker, J.
    [Show full text]
  • Allopregnanolone and Progesterone in Experimental Neuropathic Pain: Former and New Insights with a Translational Perspective
    Cellular and Molecular Neurobiology (2019) 39:523–537 https://doi.org/10.1007/s10571-018-0618-1 REVIEW PAPER Allopregnanolone and Progesterone in Experimental Neuropathic Pain: Former and New Insights with a Translational Perspective Susana Laura González1,2 · Laurence Meyer3 · María Celeste Raggio2 · Omar Taleb3 · María Florencia Coronel2 · Christine Patte‑Mensah3 · Ayikoe Guy Mensah‑Nyagan3 Received: 16 July 2018 / Accepted: 31 August 2018 / Published online: 5 September 2018 © Springer Science+Business Media, LLC, part of Springer Nature 2018 Abstract In the last decades, an active and stimulating area of research has been devoted to explore the role of neuroactive steroids in pain modulation. Despite challenges, these studies have clearly contributed to unravel the multiple and complex actions and potential mechanisms underlying steroid effects in several experimental conditions that mimic human chronic pain states. Based on the available data, this review focuses mainly on progesterone and its reduced derivative allopregnanolone (also called 3α,5α-tetrahydroprogesterone) which have been shown to prevent or even reverse the complex maladaptive changes and pain behaviors that arise in the nervous system after injury or disease. Because the characterization of new related molecules with improved specificity and enhanced pharmacological profiles may represent a crucial step to develop more efficient steroid-based therapies, we have also discussed the potential of novel synthetic analogs of allopregnanolone as valuable molecules for the treatment of neuropathic pain. Keywords Neurosteroids · Neuroactive steroids · Progesterone · Allopregnanolone · Neuropathic pain · Spinal cord · Dorsal root ganglia · Mitochondria Introduction et al. 2015; Guennoun et al. 2015; McEwen and Kalia 2010; Melcangi et al. 2014; Schumacher et al.
    [Show full text]
  • Allopregnanolone Effects in Women Clinical Studies in Relation to the Menstrual Cycle, Premenstrual Dysphoric Disorder and Oral Contraceptive Use
    Umeå University Medical Dissertations, New Series No 1459 Allopregnanolone effects in women Clinical studies in relation to the menstrual cycle, premenstrual dysphoric disorder and oral contraceptive use Erika Timby Department of Clinical Sciences Obstetrics and Gynecology Umeå 2011 Responsible publisher under Swedish law: the Dean of the Medical Faculty This work is protected by the Swedish Copyright Legislation (Act 1960:729) ISBN: 978-91-7459-316-7 ISSN: 0346-6612 Front cover: Ceramic piece in raku technique by Charlotta Wallinder Elektronisk version tillgänglig på http://umu.diva-portal.org/ Tryck/Printed by: Print & Media, Umeå University Umeå, Sweden 2011 ”Morgon. Och sakerna förbi. Och HOTET som om det aldrig funnits. Hon var inte med barn och andra eftertankar behövdes inte.” Ur Lifsens rot av Sara Lidman Table of Contents Table of Contents i Abstract iii Abbreviations v Enkel sammanfattning på svenska vi Original papers ix Introduction 1 The menstrual cycle 1 Hormonal changes across the menstrual cycle 1 Brain plasticity across the menstrual cycle 2 Premenstrual symptoms and progesterone – a temporal relationship 3 Premenstrual symptoms in the clinic 3 Epidemiology of premenstrual symptoms/PMS/PMDD 3 The symptom diagnoses of PMDD and PMS 5 Comorbidity and risk factors in PMDD 6 Treatment options for PMDD 7 Trying to understand PMDD by in vivo and in vitro research 8 Etiological considerations in PMDD 8 Brain imaging in PMDD patients across the menstrual cycle 9 Connections between the GABA system and PMDD 10 Neurosteroids 12
    [Show full text]
  • Characterisation of Serum Progesterone and Progesterone-Induced Blocking Factor
    www.nature.com/scientificreports OPEN Characterisation of serum progesterone and progesterone- induced blocking factor (PIBF) levels across trimesters in healthy pregnant women Mark Kit Lim1,5*, Chee Wai Ku2,5, Thiam Chye Tan2, Yin Hao Justin Lee1, John Carson Allen3 & Nguan Soon Tan1,4 Progesterone-induced blocking factor (PIBF), which plays an important role in maintaining healthy pregnancies, has shown great promise as a prognostic biomarker for threatened miscarriage. To better characterise the physiological trends of progesterone and PIBF, we analysed serum progesterone and PIBF concentrations in healthy non-pregnant and pregnant women across trimesters. We saw increasing concentrations of progesterone and PIBF in pregnant women with advancing trimesters. The serum progesterone and PIBF percentiles across gestational age in healthy pregnancies can be used as a guide for the formulation of reference ranges. We also demonstrated a signifcant positive correlation between progesterone and PIBF levels. This study demonstrates increasing progesterone and PIBF concentrations in later trimesters and underscores the importance of progesterone and PIBF in healthy pregnancies. Characterisation of progesterone and PIBF across gestational age in healthy pregnant women may help to prognosticate pregnancy viability and support further research into the importance of progesterone and PIBF in the maintenance of healthy pregnancies. Progesterone and progesterone-induced blocking factor (PIBF) are important in the mainte- nance of healthy pregnancies. Progesterone-induced blocking factor (PIBF), a protein comprising of 757 amino acid residues with a predicted molecular mass of 89 kDa, is important in the maintenance of human pregnancy and the progesterone dependent immunomodulation by the mother1. Progesterone has been established to inhibit myometrial contractility, and progesterone withdrawal has been linked to the start of labour2,3.
    [Show full text]